Literature DB >> 11261499

The ups and downs of multiple sclerosis therapeutics.

R Hohlfeld, H Wiendl.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11261499

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  11 in total

1.  Atacicept: targeting B cells in multiple sclerosis.

Authors:  Hans-Peter Hartung; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

2.  Axonal damage in multiple sclerosis.

Authors:  Jeffery D Haines; Matilde Inglese; Patrizia Casaccia
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

Review 3.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 4.  What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?

Authors:  Julia Krämer; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2022-07-06       Impact factor: 6.088

Review 5.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

Review 6.  Inflammation in central nervous system injury.

Authors:  Stuart M Allan; Nancy J Rothwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-10-29       Impact factor: 6.237

Review 7.  [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].

Authors:  C Kleinschnitz; S G Meuth; B C Kieseier; H Wiendl
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

Review 8.  Oral disease-modifying treatments for multiple sclerosis: the story so far.

Authors:  Bernd C Kieseier; Heinz Wiendl
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy.

Authors:  Peter O Behan; Abhijit Chaudhuri
Journal:  Inflammopharmacology       Date:  2010-09-24       Impact factor: 5.093

Review 10.  Multiple sclerosis therapy: an update on recently finished trials.

Authors:  Christoph Kleinschnitz; Sven G Meuth; Olaf Stüve; Bernd Kieseier; Heinz Wiendl
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 6.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.